BOSTON (MA), June 5, 2018 – Pfizer Canada is proud to announce a $1,200,000 contribution to the NEOMED Institute. Pfizer Canada’s support will help NEOMED in its mission to accelerate the transformation of scientific discoveries from Quebec and Canadian universities into innovative therapeutic treatments.
Over the next three years, this investment will fund new development projects for drugs that fulfil unmet medical needs and provide patients with new therapeutic solutions. Our goal is to ensure that all Canadians have access to best-in-class treatments and quality health care.
Pfizer Canada and the NEOMED Instituteare strengthening their ongoing commitment to health care innovation and research in Quebec through this partnership which supports the province’s life sciences strategy launched in May 2017.
John Helou, President of Pfizer Canada:
“We have been very pleased to support the NEOMED Institute since its inception and to participate directly in supporting the Quebec life sciences strategy. This investment fits perfectly with our strategy, collaborating innovatively with university researchers, patient organizations, governments, other biopharmaceutical companies, health care professionals and other organizations such as NEOMED, which bridge the gap between basic research and commercialization of new drugs.”
“Although this is an example of pharmaceutical investment in Canadian innovation ecosystems which does not meet the criteria of the Scientific Research and Experimental Development (SR&ED) Program, we are delighted to see that it fits in beautifully with the Government of Quebec’s action plan, intended to develop the life sciences industry.”
Donald Olds, President and Chief Executive Officer of the NEOMED Institute:
“This investment agreement marks the renewal of financial support from Pfizer Canada, one of our partners since the very beginning of NEOMED. This major investment of $1.2 million will allow NEOMED to continue bridging the gap between academic research and industry needs by investing in innovative projects to meet unmet medical needs with the goal of providing Canadians with new therapeutic solutions. It will also attract, create and facilitate a network of biotechs and CROs to ensure sustained involvement of pharmaceutical companies in discovering new drugs.”
Dr. Gaétan Barrette, Minister of Health and Social Services:
“The support of Pfizer Canada to the NEOMED Institute will accelerate the commercialization of new drugs resulting from scientific discoveries at universities and strengthen the connection between private companies, universities and research centres, to better meet the needs of patients, which is a goal of the Quebec Life Sciences Strategy.”
About Pfizer Canada Inc. –www.pfizer.ca
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, vaccines and consumer health products.Every day, Pfizer Canada employees work to bring therapies to patients that significantly improve patients’ lives. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life.Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).
About the NEOMED Institute –www.neomed.ca
The NEOMED Institute is a successful and innovative Canadian not-for-profit R&D organization whose mission is to enable and accelerate the commercialization of life science discoveries. To accomplish this mission, NEOMED Institute operates two complementary and integrated divisions:
The NEOMED Institute is funded by pharmaceutical partners, Quebec’s Ministry of the Economy of Science and Innovation, and the Networks of Centres of Excellence (NCE) of Canada as well as from revenue generated from the out-licensing/sale of their research pipeline projects and the operation of their facilities.
Pfizer Canada Media Relations: 1-866-9Pfizer (1-866-973-4937)
Tel: 514-367-1212, ext. 218
Catherine W. Audet
Cabinet du ministre de la Santé et des Services sociaux
Tél.: 418 266-7171
Office of the Minister of Health and Social Services